ERBB2 and cancer: Given the high prevalence of CKM conditions in the cancer population and their association with increased cardiotoxic risk, it is imperative to implement vigilant cardiovascular monitoring and tailored therapeutic strategies for patients undergoing HER2-targeted therapy.